Product Description
Mechanisms of Action: 5-HT2 Agonist,ADRA1A Agonist,ADRA1B Agonist,ADRA1D Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Dominican Republic | Ecuador | Egypt | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Jordan | Korea | Malaysia | Malta | Mexico | Morocco | New Zealand | Pakistan | Peru | Poland | Portugal | Russia | Serbia | Singapore | Slovenia | Spain | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|